Abstract

• The design of an ultrasensitive label-free detection of prostate specific antigen (PSA) was achieved. • The fabricated immunosensor used monoclonal anti-PSA antibody as capture probe on an electrografted isophthalic thin fim. • Capacitance signals were deconvoluted from the impedance plots and were sensitive to PSA concentrations. • The detection of PSA could be achieved in fg.ml -1 . A rapid, low-cost, and accurate point-of-care analytical device for the determination of prostate-specific antigen (PSA) is required for the early diagnosis and prognosis of prostate cancer (PCa). In this work, an electrochemical capacitive immunosensor was developed for the label-free detection of PSA. The immunosensor was based on the covalent immobilization of monoclonal anti -PSA antibody via carbodiimide chemistry onto gold electrode pre-modified with a thin monolayer film of isophthalic acid (IPA). A methodology based on the steric hindrance of 1,3-substituted aryldiazonium salt was adopted to control the growth of the IPA thin film on the gold electrode. The non-specific binding sites were blocked with bovine serum albumin (BSA) to afford an AuE-IPA- anti -PSA-mAb|BSA immunosensor. The immunosensor was characterized by X-ray photoelectron spectroscopy (XPS), cyclic voltammetry (CV), and electrochemical impedance spectroscopy (EIS). The analytical performance of the developed sensor was evaluated using the capacitance Nyquist plots generated from the complex impedance data. In addition, complex capacitance was also calculated from the imaginary part of the impedance and plotted against the log of frequency. The double layer capacitance from the circuit fitting (R S C) was also used and compared the sensitive capacitance signals to the changes in PSA concentrations. The LOD values were in fg.mL -1 and distinguishable from the blank (PBS) for the Nyquist plots of capacitance, complex capacitance, and double layer capacitance signals. The developed immunosensor exhibited good stability, selectivity, low detection limits, and a wide linear range which was suitable for screening of prostate cancer using prostate-specific antigen.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.